Last reviewed · How we verify
Mycophenolic Acid 0.1%
At a glance
| Generic name | Mycophenolic Acid 0.1% |
|---|---|
| Sponsor | Surface Ophthalmics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Advancing Transplantation Outcomes in Children (PHASE2)
- Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study (PHASE1)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)
- Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients (PHASE4)
- Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolic Acid 0.1% CI brief — competitive landscape report
- Mycophenolic Acid 0.1% updates RSS · CI watch RSS
- Surface Ophthalmics, Inc. portfolio CI